Therefore, transportation of anti-BCR/ABL antibodies into CML cells can efficiently degrade BCR/ABL proteins via the Trim-Away pathway, thus blocking the downstream signal transduction of BCR/ABL tyrosine kinases, eventually eliminating the pathogenesis of CML cells. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.